NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Actinium Pharmaceuticals, Inc. (ATNM) Stock Analysis

Actinium Pharmaceuticals, Inc. (ATNM) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

ATNM

$1.03

−$0.02 (−1.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATNM with… →

ATNM Key Statistics

As of Sep 4, 2026
Trading
Open
$1.05
Previous Close
$1.05
Day's Range
1.02–1.06
52-Week Range
0.74–1.74
Volume
54.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.05
Valuation
Market Cap
$32.32M
P/E Ratio
3.03
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.92
EPS (ttm)Profit attributable to each share over the last twelve months.
0.34
Financials (FY)
Revenue (FY)
$90.00K
Net Income (FY)
−$33.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
32.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.37M
1-Year Return
−39.05%
Dividend and dates
Avg Volume
132.71K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATNM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.26%
2025+7.94%
2024−75.20%
2023−52.30%
2022+77.20%
2021−22.95%
2020+19.27%
2019−43.67%
2018−41.72%
2017−24.11%
2016 (partial year)−47.92%

As of September 4, 2026.

ATNM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$90.00K−$33.89M−37652.2%
2024$0.00−$38.24M—
2023$81.00K−$48.82M−60269.1%
2022$1.03M−$33.02M−3205.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$90.00K—−$36.25M−$33.89M−37652.2%
2024$0.00—−$42.12M−$38.24M—
2023$81.00K—−$51.92M−$48.82M−60269.1%
2022$1.03M—−$34.10M−$33.02M−3205.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATNM Valuation vs Biotechnology Median

Median of 656 stocks
MetricATNMBiotechnology medianvs median
P/E3.0312.570.2x the median
P/S ratio0.9215.260.1x the median
Profit margin32.23%0.00%32.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Actinium Pharmaceuticals, Inc. (ATNM) is capitalised at $32.32M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 27.

Over the past 52 weeks the price has ranged from $0.74 to $1.74. The most recent close on file for ATNM is $1.03, dated September 4, 2026. That is −$0.02 (−1.90%) against the previous close. The latest close sits 40.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $90.00K. The same year closed with a net loss of $33.89M. The reported profit margin is 32.23%. That is 32.2 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.34.

Across the 4 fiscal years on file, revenue moves from $1.03M in 2022 to $90.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 3.03 times earnings. That is 0.2 times the Biotechnology median of 12.57. The price-to-sales ratio is 0.92. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −39.05%. Measured over 10 years, that is −32.31% a year compounded. The reported beta is 0.05. Annualized volatility over the trailing 10 years is 81.86%.

Growth & Income

The record shows no dividend for ATNM.

Across the complete calendar years on file, 2022 returned +77.20% and 2024 returned −75.20%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −24.26% year to date.

Peer Comparison

Actinium Pharmaceuticals, Inc. (ATNM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Actinium Pharmaceuticals, Inc. ATNM $32.32M 3.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Actinium Pharmaceuticals, Inc. trades at a P/E of 3.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Visit website →